Biofil Chemicals & Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?
- September 9, 2026
- Posted by: Harsh Piplani
- Category: Market
Biofil Chemicals & Pharmaceuticals share price Rs 31.50 (NSE), well off its 52-week high. 52-week range Rs 25.22 to Rs 46.82. Very rich valuation on thin, stagnant earnings.
Quick Answer
Biofil Chemicals & Pharmaceuticals Ltd share price is trading around Rs 31.5, more than 32 percent below its 52-week high of Rs 46.82 but above its 52-week low of Rs 25.22. The company reported full-year revenue of approximately Rs 34.3 crore with a thin profit of Rs 0.48 crore, and has delivered poor sales growth of just -4.5 percent over the past five years, with a low return on equity of just 1.24 percent averaged over three years. The stock trades at a rich 106.67 times earnings against the pharmaceutical sector average near 51.2 times, a valuation that appears disconnected from the company’s stagnant underlying growth history, warranting particular caution.
Biofil Chemicals & Pharmaceuticals share price has fallen more than 32 percent from its 52-week high of Rs 46.82, with Biofil Chemicals & Pharmaceuticals share price now trading near Rs 31.5 on the NSE, above its 52-week low of Rs 25.22. Given a very rich valuation set against a stagnant sales growth history, this article presents the numbers plainly before laying out a careful, cautious view.
This Biofil Chemicals & Pharmaceuticals overview walks through the company’s thin trailing profitability, the mismatch between its valuation and growth history, shareholding pattern and the technical setup, using figures sourced from public filings.
Click Here – Get Free Investment Predictions
About Biofil Chemicals & Pharmaceuticals
Before deciding on Biofil Chemicals & Pharmaceuticals share price, it helps to understand the underlying business. Biofil Chemicals and Pharmaceuticals Ltd., incorporated in 1985 and based in Indore, manufactures basic drugs and chemicals, and also provides job work services for pharmaceutical drug manufacturing to other companies, operating through Pharmaceutical, Chemicals and Plastic Division segments.
The company has delivered poor sales growth of just -4.5 percent over the past five years, with a low return on equity of just 1.24 percent averaged over three years, reflecting a truly stagnant underlying business that investors should weigh carefully against the stock’s current valuation.
Biofil Chemicals & Pharmaceuticals Share Price Today: Key Levels
The table below summarises where Biofil Chemicals & Pharmaceuticals share price stands right now against its recent trading range and market value.
| Metric | Value |
|---|---|
| Biofil Chemicals & Pharmaceuticals CMP (NSE) | Rs 31.50 |
| Biofil Chemicals & Pharmaceuticals CMP (BSE) | Rs 31.26 |
| 52-Week High | Rs 46.82 |
| 52-Week Low | Rs 25.22 |
| Market Capitalisation | Approximately Rs 52 crore |
Biofil Chemicals & Pharmaceuticals share price is trading well below its 52-week high, reflecting limited market attention typical of this small, stagnant pharmaceutical company.
Check the Univest Screener for Live Stock Data
Biofil Chemicals & Pharmaceuticals Financial Performance
The Biofil Chemicals & Pharmaceuticals share price trend is closely tied to how these numbers evolve each quarter. Biofil Chemicals & Pharmaceuticals reported full-year revenue of approximately Rs 34.3 crore with a thin net profit of Rs 0.48 crore, reflecting a business generating minimal profitability on a small revenue base. Notably, the company has delivered poor sales growth of just -4.5 percent over the past five years, indicating the business has not meaningfully expanded over an extended period.
Current-quarter financial data specific to the most recent period was not consistently available across public sources at the time of writing. Investors should refer directly to the company’s latest exchange filings for updated quarterly figures before drawing conclusions about the current trend.
| Period | Revenue | Net Profit | Comment |
|---|---|---|---|
| Most recent confirmed full year | Rs 34.3 crore | Rs 0.48 crore | Poor 5-year sales growth of -4.5%; ROE just 1.24% over 3 years |
Valuation Check: Is Biofil Chemicals & Pharmaceuticals Share Price Expensive?
Any view on Biofil Chemicals & Pharmaceuticals share price should start from these valuation multiples. Biofil Chemicals & Pharmaceuticals share price currently reflects a price to earnings ratio of about 106.67 times trailing earnings, a very significant premium to the broader pharmaceutical sector average of roughly 51.2 times. Given the company’s stagnant five-year sales growth of -4.5 percent and low three-year average return on equity of just 1.24 percent, this rich valuation appears disconnected from the underlying business trend.
The price to book ratio stands near 2.4 times. Debt to equity of 0.14 is low. Investors should treat this rich valuation with real caution given the mismatch with the company’s stagnant growth history.
Technical Signals: What the Chart Shows
Price action here often foreshadows the next move in Biofil Chemicals & Pharmaceuticals share price. Biofil Chemicals & Pharmaceuticals share price is currently positioned more than 32 percent below its 52-week high of Rs 46.82 and above its 52-week low of Rs 25.22. Given the very thin trading volumes and small scale typical of this stock, technical signals should be read with particular caution.
Investors should track Biofil Chemicals & Pharmaceuticals share price alongside any updated company disclosures, rather than relying on price action alone given the significant valuation-growth mismatch currently present.
Download the Univest iOS App or Univest Android App to track Biofil Chemicals & Pharmaceuticals’ live price and technical levels.
Shareholding Pattern
Shifts here can influence Biofil Chemicals & Pharmaceuticals share price more than headline news on some sessions. Biofil Chemicals & Pharmaceuticals is a small, promoter-led pharmaceutical formulations and job-work manufacturer based in Indore. Promoter holding stands at approximately 46.8 percent based on available data, and a detailed current FII and DII percentage breakdown was not consistently available across sources at the time of writing and should be verified on the company’s latest exchange filing.
Why Investors Are Watching Biofil Chemicals & Pharmaceuticals
- Low financial leverage: A debt to equity ratio of just 0.14 gives the company reasonable financial flexibility despite its stagnant growth.
- Diversified job-work pharmaceutical services: The company’s job-work manufacturing services for other pharmaceutical firms provide a supplementary revenue stream alongside its own product manufacturing.
Risks and Factors to Watch
- Very rich valuation disconnected from growth: A 106.67x PE stands in stark contrast to the company’s poor five-year sales growth of -4.5 percent, a mismatch that warrants real caution.
- truly stagnant underlying business: The company’s low three-year average return on equity of just 1.24 percent and negative five-year sales growth trend indicate a business that has not meaningfully expanded over an extended period.
- Very thin trailing profitability: A full-year net profit of just Rs 0.48 crore on Rs 34.3 crore of revenue leaves very little margin for error.
- Small-cap liquidity risk: As a small company with a market capitalisation of approximately Rs 52 crore, trading liquidity can be more limited than larger pharmaceutical peers.
Biofil Chemicals & Pharmaceuticals Share Price Target: What the Data Suggests
Until then, Biofil Chemicals & Pharmaceuticals share price remains best tracked through live, verified data rather than a single fixed number. Biofil Chemicals & Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the significant valuation-growth mismatch involved.
Investors considering this stock should seek the company’s most recent exchange filings directly, and should consult a SEBI-registered investment adviser given the rich valuation on a stagnant growth history.
Biofil Chemicals & Pharmaceuticals: Should You Buy, Hold, or Sell Right Now?
This is the core question behind Biofil Chemicals & Pharmaceuticals share price right now. The Biofil Chemicals & Pharmaceuticals buy or sell decision should weigh the rich valuation against the stagnant underlying growth.
The case for buying: Only investors who have independently identified a specific catalyst for growth to resume may consider a position, given the current mismatch between valuation and the five-year sales trend.
The case for holding: Existing shareholders who already accept this risk profile may choose to continue holding.
The case for avoiding: Most investors, particularly those seeking companies where valuation aligns with growth history, would reasonably prefer to avoid this stock given the current mismatch.
Given the valuation concerns here, consult a SEBI-registered investment adviser before proceeding.
Conclusion
Biofil Chemicals & Pharmaceuticals share price reflects a small pharmaceutical company trading at a rich valuation despite a truly stagnant five-year sales growth history, trading well below its 52-week high. This article is for informational purposes and not a personalised investment recommendation.
Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).
Q1. Is Biofil Chemicals and Pharmaceuticals a good stock to buy right now?
Ans. Biofil Chemicals & Pharmaceuticals trades at a rich 106.67 times earnings despite poor five-year sales growth of -4.5 percent and a low three-year average return on equity of just 1.24 percent. This mismatch between valuation and growth history warrants particular caution.
Q2. What is the Biofil Chemicals and Pharmaceuticals share price today?
Ans. Biofil Chemicals & Pharmaceuticals share price is trading around Rs 31.5 on the NSE. The stock’s 52-week high is Rs 46.82 and its 52-week low is Rs 25.22.
Q3. What is the Biofil Chemicals and Pharmaceuticals share price target?
Ans. Biofil Chemicals & Pharmaceuticals does not have a single widely published, current analyst consensus 12-month share price target consistently available at this time, given the significant valuation-growth mismatch involved.
Q4. What does Biofil Chemicals and Pharmaceuticals do?
Ans. Biofil Chemicals and Pharmaceuticals manufactures basic drugs and chemicals, and provides job work services for pharmaceutical drug manufacturing to other companies.
Q5. Is Biofil Chemicals and Pharmaceuticals growing?
Ans. No, the company has delivered poor sales growth of just -4.5 percent over the past five years, indicating a truly stagnant underlying business.
Q6. What is Biofil Chemicals and Pharmaceuticals’ market capitalisation?
Ans. Biofil Chemicals & Pharmaceuticals has a market capitalisation of approximately Rs 52 crore.
